Product Brief
Tirzepatide is a dual GIP/GLP-1 receptor agonist — one of the most advanced peptides in metabolic and weight-management protocols today. It works on two incretin pathways simultaneously, offering a distinct profile compared to GLP-1-only compounds.
By activating both GIP and GLP-1 receptors, Tirzepatide offers a broader metabolic profile than single-pathway incretin agonists. It is widely chosen for advanced body-composition programs where dual incretin signaling is desired.
Every Radiptide batch is manufactured under strict quality control and tested for identity and purity. Certificate of Analysis (COA) available on request.